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S U M M A R Y
Objective: To estimate the burden of HIV neurocognitive impairment (NCI) among adult patients on and
off antiretroviral therapy (ART) in Sub-Saharan Africa.
Methods: Estimates were derived from a random effects meta-analysis of prospective studies reporting
HIV status, utilization of ART, and the presence of NCI determined using the International HIV Dementia
Scale.
Results: Sixteen studies with quality data from seven countries in Sub-Saharan Africa up to June 2012
were included. Among HIV patients, the frequency of NCI pre-ART was 42.37% (95% conﬁdence interval
(CI) 32.18–52.56%), and among those on ART for 6 months was 30.39% (95% CI 13.17–47.61%).
Respective NCI estimates in studies from Uganda were 46.49% (95% CI 30.62–62.37%) and 28.50% (95% CI
1.31–58.30%). NCI was more common among patients with a concomitant psychiatric ailment. HIV-
positive patients compared to HIV-negative controls were predisposed to NCI (odds ratio (OR) 6.49, 95%
CI 1.68–25.08); the estimated unadjusted attributable risk of HIV infection leading to NCI was 85%. Meta-
regression showed no associations between age, gender, CD4 cell counts, or years of education with NCI.
Patients on ART were less likely to have NCI compared to HIV-infected pre-ART patients, with OR 0.36
(95% CI 0.19–0.69). In longitudinal studies with the same patients followed before and at 6 months
after ART, the OR of NCI after ART compared to pre-ART was 0.23 (95% CI 0.14–0.37). The combined
burden of NCI among pre-ART and on-ART patients in Sub-Saharan Africa was estimated at 8 121 910
(95% CI 5 772 140–10 471 680). No publication bias was observed, although residual confounding from
differing environmental factors, stages of HIV infection, and viral clades might be a limitation.
Conclusions: HIV strongly predisposes to NCI leading to a huge burden in Sub-Saharan Africa, and scale-
up of ART can substantially reduce it.
 2013 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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jou r nal h o mep ag e: w ww .e lsev ier . co m / loc ate / i j id1. Introduction
HIV infection is a major cause of neurocognitive impairment
(NCI).1 In Sub-Saharan Africa the burden of NCI is likely to be huge
given the substantial burden of HIV infection in the region.2,3 Early
in the epidemic, several studies assessed the presence of NCI
among infected adults, with variable results arising from
differences regarding the dominant viral clade, methods used* Corresponding author.
E-mail addresses: abdulrazaq_habib@yahoo.co.uk,
abdulrazaq_habib@hotmail.com (A.G. Habib).
1201-9712/$36.00 – see front matter  2013 International Society for Infectious Disea
http://dx.doi.org/10.1016/j.ijid.2013.06.011for NCI detection, stage of infection, and whether patients were on
or off antiretroviral therapy (ART).4–8
Successive attempts have been made to harmonize and unify
the deﬁnition and nosology of NCI, eventually culminating in a
deﬁnition formulated by the American Academy of Neurology in
2007 (AAN2007) referred to as HIV Associated Neurocognitive
Deﬁcits (HAND).5,6 This categorizes subjects into ‘normal asymp-
tomatics’, ‘asymptomatic neurocognitive impairment’ (ANI), ‘mild
neurocognitive deﬁcit’ (MND), and the severest form referred to as
‘HIV-associated dementia’ (HAD),6 previously referred to as ‘AIDS
dementia complex’ (ADC). As the neuropathological correlate of
NCI is thought to be primarily of sub-cortical origin, assessment
methods used in Sub-Saharan Africa for cortical diseases may beses. Published by Elsevier Ltd. All rights reserved.
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adapt and standardize more sensitive assessment tools and test
batteries, mindful of local cultures, ease of administration,
interpretation, and comparability between populations. This has
led to the use of the extensive multi-domain test batteries largely
in industrialized countries (e.g., the full or modiﬁed versions of the
HIV Neurobehavioral Research Center, University of California San-
Diego (HNRC) battery) and the less extensive but more easily
administered screening tools such as the International HIV
Dementia Scale (IHDS) mostly used in developing countries,
especially in Sub-Saharan Africa.7 The IHDS examines the three
main domains of motor speed, psychomotor speed, and memory
registration/recall. It consists of three subtests: timed ﬁnger
tapping, timed alternating sequence test, and registration/recall of
four items at 2 min.7
A previous meta-analysis and a systematic review addressed
detailed neuropsychological proﬁles and NCI among HIV-infected
patients before and after the highly active antiretroviral therapy
(HAART) era.8,9 In these reviews, data presented were extracted
from studies conducted worldwide with varied tools, and no point-
estimates could be derived thereby limiting their epidemiological
signiﬁcance, especially in Sub-Saharan Africa. In this study, a
systematic review and meta-analysis of studies that used IHDS was
conducted to obtain more precise prevalence estimates of NCI,
approximate the burden of NCI, and approximate the potential
impact of ART on NCI among HIV-infected adults in Sub-Saharan
Africa.
2. Materials and methods
This study was conducted and reported in accordance with the
following available guidelines: Meta-analysis of Observational
Studies in Epidemiology (MOOSE) and Preferred Reporting Items
for Systematic Reviews and Meta-analysis (PRISMA) state-
ments.10,11 To build up the meta-analysis and systematic review,
we searched for relevant English-language papers in MEDLINE, the
Cochrane Database, African Journals On-Line (AJOL) database,
Global Health, PsycINFO, existing systematic reviews, specialty
journals, other search engines, e.g. Google, and several websites.
Medical subject heading (MeSH) terms were used in the search.
‘Africa’, ‘AIDS’, ‘adults’, cognition’, ‘cognitive deﬁcit’, ‘cognitive
impairment’, ‘dementia’, ‘depression’, ‘HIV’, ‘impairment’, ‘memo-
ry’, ‘mental’, ‘neuro-cognitive impairment’, ‘neuro-psychological
impairment’, ‘neuro-psychiatric’, ‘psychological impairment’, ‘Sub-
Saharan Africa’, and ‘studies’ were used in various combinations as
primary search keywords, with no period restriction until the end
of June 2012. The review was restricted to studies that deﬁned NCI
using IHDS among adults aged 18 years, with HIV-1 (excluding
HIV-2) infections, and to Sub-Sahara Africa. We also used our
knowledge, experiences, and discussions with colleagues and
recognized experts, as well as previous publications on the subject.
When required, we contacted authors and also manually searched
the reference lists of all identiﬁed publications and recent
systematic reviews. Books, chapters, and review articles on the
subject were also consulted.
2.1. Selection criteria
Two reviewers independently assessed each potentially rele-
vant study for eligibility. Disagreements were resolved by
consultation with a third reviewer. The full texts of all accessible
English-language studies evaluating or reporting on NCI among
HIV-infected adults in Sub-Saharan Africa were selected, applying
the following inclusion criteria: (1) prospective observational
studies that used IHDS for detecting NCI; and (2) when HIV status
and ART use was stated or could be discerned. Studies wereexcluded if they did not fulﬁll the inclusion criteria (e.g., if they did
not use IHDS or deﬁned NCI clinically), or lacked or had insufﬁcient
data or desired information.
2.2. Data extraction
Data were dredged, ascertained, and obtained on a standardized
form used to record relevant items and entered into a database; the
following were recorded: study characteristics, authors, year of
publication, country, study design, setting, test battery, cut-off
scores for deﬁning NCI, age of participants, gender, HIV status and
stage of infection, formal education, CD4 cell counts, proportion of
participants with NCI, duration of ART, viral clades, potential
confounders, sources of bias, quality measures, and comments.
Another reviewer checked the extracted data for accuracy.
2.3. Quality assessment
The study quality was assessed using a modiﬁed version of the
Downs and Black checklist,12 and assessment included other items
also known to be associated with study quality.
2.4. Data analysis
The prevalence of NCI as a percentage with the respective 95%
conﬁdence interval (95% CI) was calculated for each study, among
HIV-infected adults on or off ART and among HIV-uninfected
controls. We also determined the odds of NCI as the number of
patients who developed it divided by the number of HIV-infected
patients who did not develop it for HIV-infected adults on/off ART
and for HIV-negative controls for relevant studies. When no or zero
NCI cases were found in the numerator, we added 0.5 to the
numerator and denominator of both groups when estimating the
odds.13 We did not assume zero NCI cases when this was not
reported among controls, only when it was stated. The odds ratio
(OR) and respective 95% CI for NCI in the HIV-positive compared to
the HIV-negative control group and for those on ART compared to
those off ART were calculated. The log OR and the standard error of
log OR were computed for the respective studies. Meta-analyses
were then conducted for prevalence estimates and for the OR from
comparative studies.14 Because of the differences expected
between studies, we combined results and obtained meta-analysis
estimates using a random effects model (REM). We evaluated for
statistical heterogeneity by conducting tests of between-study
heterogeneity and I2 statistics with I2 > 50% denoting substantial
heterogeneity. Sensitivity analyses primarily consisted of investi-
gating the inﬂuence of a single study on the overall summary
estimate.15 Restricted scenario analyses were then performed on
data derived from studies with distinct characteristics. Publication
bias and small study effect were assessed using adjusted rank
correlation tests and the regression asymmetry test, termed Begg’s
and Egger’s tests.16,17 Given inconsistency and the insensitivity of
the tests,17–19 publication bias was considered to exist only if
detected in both tests. The crude attributable risk and population
attributable risk percent were computed using the REM-derived
OR with Levin’s formula.20 We also performed univariate,
weighted, least-squares meta-regressions to identify study-level
characteristics (mean or median age of participants, years of formal
education, CD4 cell counts, and proportion of female participants)
associated with the risk of NCI.21 The estimates derived for the
prevalence of NCI among the HIV-infected on and off ART were
applied to the total adult HIV-infected populations on and off ART
in Sub-Saharan Africa, respectively.22 The two were then summed
to give an estimated burden of NCI in Sub-Saharan Africa. All
analyses were carried out using Stata version 11.0 (Stata Corp.,
College Station, TX, USA).
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A ﬂow diagram of the process of article selection for the meta-
analysis and review is shown in Figure 1.
3.1. Overview of selected studies
Forty-six studies were initially screened.4,7,23–66 Subsequently,
studies were dropped if they used diagnostic batteries other than
IHDS,4,23–26,28–31,33,35,37,38,44,46–52,57–65 had mixed data that could
not be differentiated into participants on/off ART,57–59 if they did
not otherwise fulﬁll inclusion criteria, or if the publications were
duplicated.62,63 Studies were also dropped if they used the HIV
Dementia Scale (HDS),33,35,58,62,64 or used the IHDS but did not
allow delineation of NCI.65 Sixteen main studies satisﬁed the
inclusion criteria and were of satisfactory quality.7,27,32,34,36,39–
43,45,53–56,66 Characteristics of the studies and quality indices
assessed are presented in Tables 1 and 2. The studies were from
seven countries in Sub-Saharan Africa, comprising South Africa
(n = 4), Uganda (n = 6), Zambia (n = 2), Botswana (n = 1), Cameroon
(n = 1), Malawi (n = 1), and Nigeria (n = 1). These 16 studies had
point-prevalence for NCI in HIV-infected adult patients pre-ART
(n = 7),7,32,36,42,43,45,46 at 6 months on ART (n = 4),53–56 or at both
times (n = 5);27,34,39,40,66 three of the latter studies were longitu-
dinal and had NCI prevalence computed for the same subjects at
both pre-ART and 6 months after commencement of ART27,39,66
(Table 1). All ﬁve studies showed lower prevalence of NCI after 6
months on ART compared to off- or pre-ART (Table 1). All theFigure 1. Flow diagram of the process of article studies used an IHDS cut-off of 10 for the deﬁnition of NCI except
two studies that used 9.5 and <10.5, respectively,53,54 although
the former used additional cognitive tests.53 Further to using IHDS
with a cut-off of 10, four studies used additional tests, and their
combined assessments were used to assign a Memorial Sloane
Kettering (MSK) dementia stage.7,27,36,66 Six of the 16 studies had a
healthy/HIV-negative control group; NCI was detected among
controls in three of the studies, while the remaining three studies
only generated normative data and cut-offs for deﬁning NCI among
the controls (Table 1). Most of the studies were cross-sectional
(n = 12) and the remaining studies were either cohort (n = 1) or
longitudinal (n = 3).
3.2. Characteristics of participants in studies
The proportion of female participants reported in 15 studies
ranged from 50% to 79.2%. The mean or median ages of participants
in 15 studies ranged from 29.75 to 40 years. The mean or median
duration of formal education among participants in nine studies
ranged from 7.2 to 10.5 years. Mean or median CD4 cell counts
were reported in 10 studies and ranged from 35 to 360.4 cells/ml.
Participants recruited in the studies comprised asymptomatic HIV
patients (n = 1), a mixed group of asymptomatic and symptomatic
infections (n = 3), and symptomatic stable patients (n = 12). Four
studies recruited participants with CD4 cell counts <200 cells/
ml.27,32,36,39 Several studies evaluated the functional activity and
performance status of participants using the Karnofsky scale and
excluded those with Karnofsky scale <50%. HIV viral load wasselection for the meta-analysis and review.
Table 1
Characteristics of included studies on neurocognitive impairment in HIV-1-infected adults in Sub-Saharan Africa
Study
No.
Author, year, Ref. Country Study design Symptom status CD4 cell count Demographics Prevalence of NCI between groups
(HIV-pos/neg or ART+/) (n/N)
Comments, observations,
or sources of bias
Age, years Females
(%)
Years of
education
HIV-pos, ART,
(NCI/total (%))
HIV-neg
(NCI/total (%))
HIV-pos
ART+
(NCI/total (%))
1. Sacktor et al., 20057 Uganda C-S Symp - 37.0 (9.4) - 8.7 25/81 (30.86) NR/100 - Excluded Karnofsky <50
and other confounders
2. Sacktor et al., 200627 Uganda Longitudinal Symp
CD4 <200
71 (15) 32.8 (1.3) 77 8.7 14/23 (60.87) - 1/21 (4.76) Excluded Karnofsky <50
and other confounders;
practice effect present
3. Breuer et al., 201154 South Africa C-S Asymp - 37 (31–42) 64 - - 30/259 (11.58) Alcohol and psychiatric
diseases not excluded;
screened by nurses and
lay counselors
4. Lawler et al., 201053 Botswana C-S Symp 360.4 (181.4) 37.5 (23–50) 50 8.9 - - 46/120 (38.33) Done in urban setting;
80% had viral load <400
copies/ml
5. Robbins et al., 201156 South Africa C-S Symp 296.1 (162.8) 38.5 (9.26) 65 - - 52/65 (80.00) Ethanol not excluded;
assessed psychiatric
diseases
6. Singh et al., 200832 South Africa C-S Symp
CD4 <200
35a 34.0a 60 16/20 (80.00) - - 60% had depression
7. Birbeck et al., 201141 Zambia Prospective
cohort
Asymp/Symp - 38.1 (9.5) 58.7 7.2 185/440 (42.05) Neuropsychiatric patients
recruited; assessed
adherence and stigma; no
CD4 count
8. Holguin et al., 201142 Zambia C-S Asymp/Symp - 34.0 64.8 9 12/54 (22.22) NR/57 - No CD4 count; excluded
ethanol and depression;
psychiatric disease not
excluded
9. Joska et al., 201143 South Africa C-S Symp 218.09 (150.57) 29.75 (3.67) 79.2 10.05 65/96 (67.71) NR/94 - ART-naı¨ve; HCV not
screened
10. Patel et al., 201040 Malawi C-S Symp - 36.7 65 7/45 (15.56) - 18/134 (13.43) CD4 count not reported
11. Nakasujja et al., 201039 Uganda Longitudinal Symp
CD4 <200
130 (69.5) 34.2 (6.2) 72.6 9.1 70/102 (68.63) 4/25 (16.00) 28/93 (30.11) Assessed functional
status; depressive
patients found; small
number of controls
12. Njamnshi et al., 200934 Cameroon C-S + control Asymp/Symp 264.5 (194.2) 37.6 (8.8) 67 28/109 (25.69) - 13/76 (17.11) Excluded confounders
13. Sacktor et al., 200936 Uganda C-S + control Symp
CD4 <200
355 (136.3) 34.63 (2.35) 65 10.5 21/60 (35.00) - - IHDS 10 in all cases;
excluded confounders; 8
of 9 subtype D and 7 of 33
subtype A had dementia
14. Nakimuli-Mpungu
et al., 201155
Uganda C-S Symp - 40a (18–80) 69.8 - - 314/500 (62.80) 46% of subjects had
depression
15. Sacktor et al., 200966 Uganda Longitudinal
(6 months)
Symp 129 (79) 34.2 (6.4) 72 9.1 40/102 (39.22) 0/25 (0.00) 15/95 (15.79) Excluded OIs clinically;
IHDS 10 in all cases
16. Royal et al., 201245 Nigeria C-S + control Symp 178.9 (206.8) ?? 61.7 17/60 (28.33) 9/56 (16.07) - NCI associated with
subtype G virus
ART, antiretroviral therapy; ART+, on ART for at least 6 months; ART, not on ART; Asymp, asymptomatic; C-S, cross-sectional; IHDS, International HIV Dementia Scale; NR, not reported; OIs, opportunistic infections; Symp,
symptomatic.
Data are mean (SD) or median (IQR). Cofounders include ethanol, depression, psychiatric diseases, opportunistic infections, low Karnofsky score, and comorbid conditions. Some studies did not exclude all of them.
a Median (interquartile range).
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A.G. Habib et al. / International Journal of Infectious Diseases 17 (2013) e820–e831e824reported in studies from Botswana and Nigeria.45,53 Studies
addressed other potential confounders and some excluded
participants with psychiatric morbidity, ethanol/substance use,
and possible central nervous system (CNS) opportunistic infections
(OIs) (Tables 1 and 2).7,27,34,36,40,42,43,45,66
3.3. Findings from the meta-analysis
3.3.1. Prevalence of NCI among those not on ART
The REM estimates of NCI among HIV-infected adults pre-ART
from 12 studies was 42.37% (95% CI 32.18–52.56%) (Figure 2).
There was no publication bias (Begg’s test, p = 0.945; Egger’s test,
p = 0.827) (Figure 7a). Sensitivity analysis showed that no study
unduly inﬂuenced the ﬁndings (Figure 3).
In the six studies from Uganda,7,27,36,39,55,66 the REM pooled
estimates of NCI among infected patients pre-ART was 46.49% (95%
CI = 30.62–62.37%). While the corresponding estimates was
28.50% (95% CI = 1.31–58.30%) for patients on ART from 4 studies.
The prevalence of NCI among ART-naı¨ve patients reported by two
studies each from South Africa and Zambia is given in Table 1.
In an REM meta-analysis comprising nine stud-
ies,7,27,34,36,40,42,43,45,66 where those with active psychiatric disease,
use of anti-psychiatric medication, alcohol or substance use were
excluded, the prevalence estimate of NCI was 35.66% (95% CI 24.44–
46.87%). The pooled estimate from three studies32,39,41 that included
participants with psychiatric diseases or substance use was 62.56%
(95% CI 39.28–85.84%).
Meta-regression was conducted only on studies reporting
NCI pre-ART or off-ART. In the analysis, study-speciﬁc NCI
estimates showed no signiﬁcant associations with four study-
level characteristics: mean/median age of patients in years
ranging from 29.5 to 38.1 years had a slope coefﬁcient of 4.95
(95% CI 10.07 to 0.16, p = 0.056) in 12 studies; the slope of the
line in the relationship with the proportion of women across a
wide range from 50% to 79.2% had a coefﬁcient of 1.06 (95% CI
4.49 to 6.60, p = 0.680) in 12 studies; the slope of the line in
the relationship with mean/median formal years spent in
education across a wide range from 7.2 to 10.5 years had a
coefﬁcient of 2.49 (95% CI 14.95 to 19.94; p = 0.739) in eight
studies; and the slope of the line in the relationship with mean/
median CD4 cell counts across a wide range from 35 to 355 cells
per ml had a coefﬁcient of 0.13 (95% CI 0.29 to 0.035;
p = 0.103) in eight studies (Figure 4).
When compared to HIV-negative adult controls, the OR for
developing NCI in HIV-infected adults was 6.49 (95% CI 1.68–
25.08) (Figure 5). There was no publication bias (Begg’s test,
p = 0.602; Egger’s test, p = 0.469.). Sensitivity analysis showed
none of the studies unduly weighed on the estimates. The
estimated unadjusted attributable risk of HIV infection leading
to NCI was 85% and the population attributable risk percent was
estimated as 9.89% assuming a conservative 2.0% adult HIV
seroprevalence in Sub-Saharan Africa.20,22
3.3.2. Prevalence of NCI among those on ART
The REM estimate of NCI among HIV-infected adults on ART for
6 months from nine studies27,34,39,40,53–56,66 was 30.39% (95% CI
13.17–47.61%) (Figure 6). There was no publication bias (Begg’s
test, p = 0.175; Egger’s test, p = 0.287). The sensitivity analysis
showed that no study unduly inﬂuenced the ﬁndings.
When ﬁve studies reporting on NCI among those on ART
compared to pre-ART were analyzed, the pooled REM OR was 0.36
(95% CI 0.19–0.69) with no publication bias (Begg’s test, p = 0.462;
Egger’s test, p = 0.914) (Figures 7b and 8). Three of the ﬁve were
longitudinal studies with the same patients followed before and at
6 months after ART yielding an OR of NCI after ART compared to
pre-ART of 0.23 (95% CI 0.14–0.37).
Figure 2. Prevalence (%) of neurocognitive impairment in HIV-infected adults in Sub-Saharan Africa (pre-ART or off ART).
Figure 3. Sensitivity analyses showing effect of dropping individual studies on pooled REM prevalence (%) estimates of remaining 11 studies (combined estimates from the 12
comparisons are depicted by the 3 vertical lines).
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Figure 4. Meta-regression of NCI in HIV infected adults (pre-ART) by study-level parameters.
A.G. Habib et al. / International Journal of Infectious Diseases 17 (2013) e820–e831e8263.3.3. Burden of NCI in Sub-Saharan Africa
The burden of NCI was obtained as sum of product of 42.37%
(95% CI 32.18–52.56%) of HIV-infected adults not on ART (assumed
16 300 000; UNAIDS 2009) and the product of 30.39% (95% CI
13.17–47.61) of HIV-infected on ART (assuming 80% of the 5
million patients on ART are adults, i.e., 4 million adults (ONE
International)).67 Thus, the combined burden of NCI among pre-
ART and on-ART patients totaled 8 121 910 (95% CI 5 772 140–
10 471 680) in Sub-Saharan Africa.
4. Discussion
This study conﬁrmed that HIV infection is a major predisposing
factor for NCI, leading to a huge burden of over 8.1 million adult
patients in Sub-Saharan Africa. It reafﬁrmed that ART confers
substantial beneﬁt against NCI, lowering it by over 60%. Indeed, the
burden may be an underestimation, as a higher prevalence of NCI
has been reported in some studies,39,43 and ANI could not be
assessed with the IHDS, although there is controversy surrounding
its existence as an entity.68 Furthermore, applying the lower
prevalence of 30.39% to the HIV-infected patients on ART (4
million)67 and the exclusion of children, adolescents, and HIV-2infections, yielded lower burden estimates. The overall estimates
are similar to the 8 million derived from studies conducted in
Uganda.7,69
In Sub-Saharan Africa, patients generally present with a more
advanced symptomatic infection, often with anemia, poor perfor-
mance status, wasting and severe immunosuppression with low
CD4 cell counts, conditions known to predispose to NCI.1,30,39
Perhaps this accounts for the higher NCI prevalence recorded
compared to the cumulative lifetime risk of developing NCI from
well-conducted cohort studies in developed countries, as in the
USA where 15–20% was observed in the Multicenter AIDS Cohort
Study in the pre-HAART era.70
A previous meta-analysis reported on the indices traditionally
used in psychological studies, such as quantiﬁcation of the effect
size and assigning of impairment ratings from comparisons with
normative data among controls.8 This was not adopted in this
review. The strengths of our approach include an ability to derive
an accurate point prevalence and therefore burden of NCI. This
would not have been feasible with the former approach. Several
studies and previous systematic reviews have suggested that ART
has beneﬁcial effects on NCI, but to our knowledge no previous
report has quantiﬁed the extent of the beneﬁt.9,27,66,71 Our analysis
Figure 5. NCI among HIV infected compared to uninfected adults (Odds Ratio [95% CI]).
Figure 6. Prevalence (%) of Neuro-Cognitive Impairment (NCI) in HIV infected adults on ART in 9 studies in SSA.
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Figure 7. Publication bias on studies of NCI: (a) among patients pre- or off- ART by Egger’s plot; (b) comparing [Odds Ratio(95% CI)] of those on-ART to those off-ART by Begg’s
funnel plot.
A.G. Habib et al. / International Journal of Infectious Diseases 17 (2013) e820–e831e828suggests that ART improves NCI by 63% when compared to similar
subjects not on ART and by 77% when the same patients are tested
before and at least 6 months after commencement of ART. Such
longitudinal studies have the advantage of allowing for within-
subject assessments. However, it is likely the actual beneﬁt could
be slightly less, as serially conducted testing in the same patient
population introduces a practice effect and apparent improve-
ments in performance. Furthermore, as HIV-infected persons age,
residual long-term effects can still be seen in the brain structure
which likely stem from damage done prior to ART. As antiretroviral
(ARV) drugs have different CNS penetrating effectiveness (CPE), it
is likely the effect of ART regimens may also be variable. However,
our results strongly advocate for scale-up of HAART as an
intervention for reducing the massive burden of NCI in the region.
To improve population homogeneity, analysis was conducted
on adults only and NCI was deﬁned with the same test, the IHDS.
However, there are several sources of heterogeneity includingdifferences resulting from differing circulating HIV-1 viral clades,
and differing study designs and data quality. However attempts
were made at deriving estimates from more homogeneous
populations, e.g. from individual countries (Uganda), thereby
reducing differences from viral clades and cultural/environmental
effects. Secondly, the prevalence of NCI for those with and without
psychiatric diseases and alcohol/substance use was obtained
separately to reduce their confounding effects. NCI was higher
in studies with participants with psychiatric diseases or substance
use.32,39,41 It has been suggested that sole psychiatric presentation
may be the early phase of NCI. Indeed initial symptoms may be
subtle and are therefore easily overlooked and can be misdiag-
nosed as depression or mental retardation.72 Meta-regression of
study-speciﬁc NCI prevalence conducted to explore associations
with study-level parameters failed to conﬁrm signiﬁcant relation-
ships. However, there was a non-signiﬁcant decreasing trend in
NCI with increasing age and CD4 cell counts. Education increases
Figure 8. Effect of ART on neurocognitive impairment: estimates on ART compared to pre-ART (OR (95% CI)).
A.G. Habib et al. / International Journal of Infectious Diseases 17 (2013) e820–e831 e829the so-called cognitive ‘cerebral reserve’,73 but duration of
education had no relationship to NCI. Similarly, no association
between gender and NCI was shown, although studies have found
it to be higher among females42 or males.44
Consistent with previous reports, estimates derived from
studies in Uganda with more homogeneous viral populations
and a predominance of clades D/A yielded a higher prevalence of
NCI. It has been suggested that clade D viruses have more
neurotropic activity and generally have a more aggressive natural
history.36,74 Using IHDS and a cut-off score of 10 for deﬁning NCI,
studies in Nigeria45 and Uganda36 with circulating recombinant
form (CRF) 02AG (CRF_02AG) and clade A respectively yielded
estimates of 29% and 21%, compared to 89% reported in clade D-
infected patients in Uganda. Indeed, the preliminary analysis from
Nigeria, involving sequencing of partial pol amplicons from viral
isolates, revealed that two of three patients with NCI were infected
with subtype G virus and one with the CRF02_AG, while all four
individuals without NCI were infected with CRF_02AG.
The ﬁndings should be interpreted in the light of several
caveats. Firstly, IHDS is a screening test for NCI. Indeed, in Guinea-
Bissau it has been suggested that IHDS may be a less effective
screening tool for HAND/NCI, especially in settings of lower
educational attainment.75 Furthermore it does not assess depres-
sion and other important domains like executive functions and
may underestimate the burden of NCI. Investigators in Cameroon
using an extensive battery of 19 tests detected signiﬁcantly lower
performance on executive functions as evaluated using three tests
(Category Test, Color Trails II, and Wisconsin Card Sorting Test-64),
and South African patients with HAD, who screened negative on
the IHDS, also performed poorly on some tests of executive
functions.43,52 However, we found most investigators of NCI in
Sub-Saharan Africa assessed for psychiatric diseases including
depression,7,27,34,36,40,42,45,66 but the addition of assessmentsmissing in IHDS (e.g., executive functions) in combination will
deﬁnitely improve its accuracy. Combinations of assessments and
tests that will yield accurate results while retaining the balance of
brevity and simplicity should be explored. Secondly, only about half
of the studies included in the review excluded (or declared)
participants with active OIs or substance use. Few of the studies
excluded those with neurological comorbidities and none utilized
neuroimaging for excluding alternative diagnoses to NCI. This could
have overestimated NCI, but provides some advantages from the
point of view of generalizability of ﬁndings to diverse routine patient
populations such as exist in HIV clinics in Sub-Saharan Africa.76
Publication bias did not affect the results as our analyses using two
concurrent approaches excluded it. Bias from non-inclusion of
literature in other languages is unclear but likely to be minimal.
In conclusion, HIV strongly predisposes to NCI, leading to a huge
burden in Sub-Saharan Africa. Early commencement of ART can
improve NCI substantially, and its scale-up as an intervention for
reducing the huge burden in the region is strongly advocated.
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